TAKE A LOOK AT WHICH REPORT YOUR PORTFOLIO'S BEEN MISSING...

Shareholders Foundation offers real-time reporting of class action exposure on a per transaction basis,
including the documents you will need for claim filing and settlement recovery.
Start Monitoring Your Investments

Osiris Therapeutics, Inc. (NASDAQ: OSIR) Investor Lawsuit Over Alleged Wrongdoing In Acquisition Filed

  • Investors who purchased shares of Osiris Therapeutics, Inc. (NASDAQ: OSIR) and currently hold any of those NASDAQ: OSIR shares have certain options and should contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this case, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Lawsuit Overview

Company
Osiris Therapeutics, Inc.
Security
NASDAQ: OSIR

Case Name
Osiris Therapeutics Deal Case
Type of Lawsuit
Mergers and Acquisition
You must register or login to receive notifications.

Click here to subscribe to Osiris Therapeutics, Inc..
Summary

An investor, who currently holds shares of Osiris Therapeutics, Inc. (NASDAQ: OSIR), filed a lawsuit against the takeover of Osiris Therapeutics, Inc.
The plaintiff alleges that the defendants breached their fiduciary duties owed to NASDAQ: OSIR stockholders by agreeing to sell Osiris Therapeutics, Inc. cheaply via an unfair process.

On March 12, 2019, Osiris Therapeutics, Inc. (NASDAQ: OSIR) announced that it has entered into an agreement and plan of merger with Smith & Nephew plc pursuant to which Smith & Nephew will acquire Osiris for $19.00 per share in cash, a total of approximately $660.5 million in cash.

However, plaintiff claims that the proposed consideration NASDAQ: OSIR shareholders will receive is grossly inadequate and undervalues Osiris Therapeutics. In addition, the plaintiff alleges that the process is also unfair NASDAQ: OSIR stockholders.